2007
DOI: 10.1016/j.ahj.2007.03.027
|View full text |Cite
|
Sign up to set email alerts
|

Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: A prospective randomized controlled study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

3
46
0
1

Year Published

2008
2008
2021
2021

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 60 publications
(50 citation statements)
references
References 28 publications
3
46
0
1
Order By: Relevance
“…Heart failure was most consistently associated with all types of lipid abnormalities independent of statin treatment. Several observational studies have shown statins to be associated with reduced mortality in patients with heart failure [25]; while some randomized controlled statin trials have shown a reduction in hospitalization and improved markers [26,27,28,29], they have not demonstrated mortality in this patient population [27,29]. Factors associated with mortality in patients with heart failure are complex and are beyond the scope of this observational study.…”
Section: Discussionmentioning
confidence: 99%
“…Heart failure was most consistently associated with all types of lipid abnormalities independent of statin treatment. Several observational studies have shown statins to be associated with reduced mortality in patients with heart failure [25]; while some randomized controlled statin trials have shown a reduction in hospitalization and improved markers [26,27,28,29], they have not demonstrated mortality in this patient population [27,29]. Factors associated with mortality in patients with heart failure are complex and are beyond the scope of this observational study.…”
Section: Discussionmentioning
confidence: 99%
“…Endothelial dysfunction, characterized by reduced synthesis and release of endothelium-derived NO and decreased activity of eNOS, is an important indicator of cardiovascular diseases [4][5][6] . Increasing clinical trials have demonstrated that 3-hydroxy-3-methylgulutaryl-coenzyme A (HMGCoA) reductase inhibitors or statins reduce the risk of coronary artery disease and stroke [7,8] and function as second-line prevention of these diseases, and recently studies showed that they can improve the prognosis of heart failure [7,[9][10][11] . Although elevated plasma cholesterol level induces endothelial dysfunction and cholesterol-lowering therapy using statins can improve cardiac function in animal model [12,13] , the protective effects of statins can not be explained only by their lipid-lowering action, and mounting evidence suggests that statins, be- sides its lipid-lowering effect, can improve the functions of endothelial cells and especially up-regulate the expression and the activity of eNOS [13][14][15][16][17] .…”
mentioning
confidence: 99%
“…7 Meantime, HMG-CoA reductase inhibitors (statins) have been shown to counteract the harmful influence of smoking through their pleiotropic effects, such as antioxidative and antiinflammatory properties. 19,22 Atorvastatin has been shown to restore endothelial function in chronic smokers; 23 however, it as well as other lipophilic statins are metabolized by cytochrome P-450 (CYP) 3A4, and they have been reported to increase the risk of statin-associated adverse reactions when coadministered with other drugs that share CYP3A4 metabolism. 24 In contrast, pitavastatin is not metabolized by P-450 CYP3A4 and can avoid potential harmful drug interactions.…”
Section: Effects Of Pitavastatin On Ros Accumulation and Viability Ofmentioning
confidence: 99%